Cromolyn sodium is expensive primarily because very few companies manufacture it, several producers have recently left the market, and an ongoing drug shortage has tightened supply even further. A standard 30-day supply of the oral solution carries a retail price around $682, though discount programs can bring that closer to $138. For a decades-old generic drug, those numbers are surprisingly high, and the reasons come down to basic market dynamics rather than any complexity in the drug itself.
How a Niche Drug Ends Up With Few Manufacturers
Cromolyn sodium works by stabilizing mast cells, the immune cells that release histamine and other inflammatory chemicals during an allergic reaction. Unlike antihistamines that block histamine after it’s already been released, cromolyn prevents the release from happening in the first place. That makes it useful for a specific set of conditions: mild to moderate asthma prevention, allergic rhinitis, certain eye allergies, and systemic mast cell disease (mastocytosis). It’s also prescribed off-label for mast cell activation syndrome (MCAS), a condition that has gained significant attention in recent years.
The problem is that each of these uses serves a relatively small patient population. Asthma treatment has largely shifted toward inhaled corticosteroids and other newer therapies, leaving cromolyn as a second-line option. The patients who rely on it most heavily, those with mast cell disorders, represent a niche market. Pharmaceutical companies make production decisions based on expected sales volume, and a drug with limited demand doesn’t attract many manufacturers.
Manufacturers Leaving the Market
The number of companies making cromolyn sodium oral solution has been shrinking. Wallace Pharmaceuticals discontinued its version. Woodward Pharma, another supplier, ceased operations entirely in 2025. When manufacturers exit, the remaining producers face less competition and little pressure to lower prices.
Currently, only a handful of companies produce the oral and inhalation forms in the United States: Micro Labs Limited, Ritedose Pharmaceuticals, Ailex Pharmaceuticals, Omnivium Pharmaceuticals, and Rising Pharma Holdings. That’s a thin roster for any medication, and it creates a fragile supply chain where a single production disruption can ripple across the entire market.
An Ongoing Drug Shortage
The American Society of Health-System Pharmacists has listed cromolyn oral solution as a drug in shortage since October 2023, with the listing still active as of early 2026. Drug shortages drive prices up in predictable ways: pharmacies compete for limited stock, wholesalers raise acquisition costs, and patients sometimes pay premium prices just to find the medication at all. The shortage also means some pharmacies simply don’t carry it, forcing patients to call around or use mail-order services.
Brand vs. Generic Price Gap
Even within the generic market, pricing varies widely. The brand-name version, Gastrocrom, costs roughly $1,206 for a 480 mL supply. Generic cromolyn for the same quantity ranges from about $88 to $145 without insurance. That’s a dramatic difference, and it highlights why checking for the generic is essential. But even the generic price is steep for what is pharmacologically a simple, well-understood compound that has been available since the late 1990s. The original brand, Nasalcrom (for the nasal formulation), lost its market exclusivity back in January 2000, so there are no patent barriers keeping prices high. The issue is purely about supply and competition.
Insurance Coverage Is Inconsistent
Whether your insurance covers cromolyn sodium depends heavily on your plan and the formulation prescribed. The VA health system, for example, lists the inhalation solution as a Tier 2 formulary item, meaning it’s covered with a moderate copay and no prior authorization. But many private insurance plans treat the oral solution differently. Some don’t cover it at all for off-label uses like MCAS. Others require prior authorization, which adds delays and paperwork. If your plan doesn’t cover it, you’re facing the full retail cost.
Discount programs like GoodRx can significantly reduce out-of-pocket costs. For a 96-ampule carton of the oral solution (100 mg/5 mL), the retail price sits around $682, but a GoodRx coupon can drop that to roughly $138. That’s still not cheap for a monthly medication, but it’s a meaningful difference. Checking multiple pharmacies is worth the effort, since prices for the same drug can vary by hundreds of dollars depending on the retailer.
Why It Stays Expensive
The core issue is that cromolyn sodium exists in a pricing trap common to older generic drugs with small patient populations. It’s too niche to attract many manufacturers, too inexpensive per unit to justify major production investment, and too essential for the patients who need it to simply go without. When one or two producers drop out, prices climb. When a shortage hits, they climb further. And because there’s no close therapeutic substitute for mast cell stabilization (antihistamines and corticosteroids work through entirely different mechanisms), patients have limited ability to switch to a cheaper alternative.
This pattern isn’t unique to cromolyn. Dozens of older generic drugs have experienced similar price spikes when competition thins out. The difference is that cromolyn’s patient community, particularly those with mast cell disorders, often needs the oral formulation long-term, making the cumulative cost burden substantial. A year of treatment at the discounted rate still runs over $1,600, and at full retail, it approaches $8,000.